AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04512430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center
Study NCT04512430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo\[2,3 d\]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center
Study NCT01794962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy and exercises
Description: Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
Study NCT06187584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/acetaminophen
Description: Hydrocodone/acetaminophen 0.15mg/kg PO q6
Study NCT06187584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 15mg/kg PO q6 hours
Study NCT06187584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 10mg/kg PO q6 hours
Study NCT06187584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10mg/kg PO q6 hours
Study NCT04177394 — intervention group
Intervention type: DEVICE
Intervention: MitraClip G4 System
Description: Percutaneous mitral valve repair using the MitraClip G4 system.
Study NCT04590963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.
Study NCT04590963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants will receive IV infusion of cetuximab as stated in arm description.
Study NCT04590963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Participants will receive IV infusion of cetuximab as stated in arm description.
Study NCT04590963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusion of placebo as stated in arm description.
Study NCT00658814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC during induction; given SC during consolidation and maintenance
Study NCT00658814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study NCT04534582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX14
Description: healthy volunteers receive HLX14 (60mg) once
Study NCT04534582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia®
Description: healthy volunteers receive EU-Prolia® (60mg) once
Study NCT04534582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Prolia®
Description: healthy volunteers receive US-Prolia® (60mg) once
Study NCT04534582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CN-Prolia®
Description: healthy volunteers receive CN-Prolia® (60mg) once
Study NCT01615029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 (Dose Escalation): Daratumumab
Description: Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
Study NCT01615029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (Dose Expansion): Daratumumab
Description: Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
Study NCT01615029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
Study NCT01615029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously \[injection of a substance into a vein\]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index \[BMI\] less than \[\<\] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
Study NCT02665195 — intervention group
Intervention type: OTHER
Intervention: saliva specimen
Study NCT02665195 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Study NCT02365597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: 8 mg orally once daily for 28 days on a 28 day cycle.
Study NCT02365597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.
Study NCT02365597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
Study NCT04152291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethyl-Eicosapentaenoic Acid (E-EPA)
Description: 3,9 grams of EPA is added to participants' normal diet.
Study NCT04232345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.
Study NCT04232345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
Study NCT04657263 — intervention group
Intervention type: OTHER
Intervention: Vaccine coverage assessment
Description: Vaccine coverage assessment
Study NCT02943798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide plus carboplatin
Description: etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
Study NCT02943798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Description: Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
Study NCT04549636 — intervention group
Intervention type: OTHER
Intervention: V/Q SPECT-CT
Description: At visits 1 and 2, ventilation will be assessed by 99mTc Technegas SPECT ventilation scan and perfusion will be assessed by 99mTc Macroaggregated Albumin SPECT perfusion scan.
Study NCT04549636 — intervention group
Intervention type: OTHER
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Description: At visits 1 and 2, quality of life will be evaluated using the St. George's Respiratory Questionnaire (SGRQ).
Study NCT04549636 — intervention group
Intervention type: OTHER
Intervention: mMRC (Modified Medical Research Council) Dyspnea Scale
Description: At visits 1 and 2, dyspnea will be evaluated using the mMRC (Modified Medical Research Council) Dyspnea Scale.
Study NCT04549636 — intervention group
Intervention type: OTHER
Intervention: Six-minute walk test (6MWT)
Description: At visits 1 and 2, exercise capacity will be evaluated using the six-minute walk test (6MWT).
Study NCT03971253 — intervention group
Intervention type: DRUG
Intervention: Peficitinib
Description: Oral
Study NCT03725332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance use counselor or perinatal nurse facilitator. Consultations will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
Study NCT03725332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Care
Description: Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator or substance use counselor, with a peer support specialist. Small group care meetings will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
Study NCT04549636 — intervention group
Intervention type: OTHER
Intervention: Spirometry
Description: At visits 1 and 2, spirometry will be performed to quantify the forced expiratory volume in one second (FEV1), the forced vital capacity (FVC) and FEV1/FVC.
Study NCT04549636 — intervention group
Intervention type: OTHER
Intervention: Plethysmography & DLCO
Description: At visits 1 and 2, plethysmography and the diffusing capacity of the lung for carbon monoxide (DLCO) will be performed.
Study NCT03109288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15-45 mg po qd
Study NCT03109288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clemastine fumarate
Description: 8 mg/day (divided into 3 doses of 2, 2, and 4 mg)
Study NCT03109288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: Up to 200 mg/day (divided into 3 doses of 50mg, 50mg, and 100 mg)
Study NCT03109288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Up to 801 mg po tid. Slow titration over weeks based on tolerability:~267mg po tid x >= 7d 534 mg po tid x >= 7d 801 mg po tid
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - AZD9291 in combination with AZD6094
Description: Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)
Description: Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
Description: Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - AZD9291 in combination with intermittent selumetinib
Description: Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A - AZD9291 in combination with MEDI4736
Description: Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B - AZD9291 in combination with AZD6094
Description: Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B - AZD9291 in combination with selumetinib
Description: Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent \[4 days on/3 days off\]) to further investigate the safety and tolerability of this combination.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B - AZD9291 in combination with MEDI4736
Description: Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C - AZD6094 monotherapy (Japan only)
Description: Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C - AZD9291 in combination with AZD6094 (Japan only)
Description: Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
Study NCT02143466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part D - AZD9291 in combination with AZD6094
Description: Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
Study NCT04549636 — intervention group
Intervention type: OTHER
Intervention: Airwave Oscillometry
Description: At visits 1 and 2, airwave oscillometry will be performed to obtain resistance (R) and reactance (X) at 5 Hz (R5) and 19 Hz (R19). The resonance frequency (fres), area above the reactance curve (AX) and the heterogeneity of obstruction (R5-19) will be derived from R and X.
Study NCT05135936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hyperthermia Group
Description: The first hyperthermia treatment of the series is carried out for the second aptitude test, directly following the randomisation in the intervention group at the Hospital for Naturopathy and Integrative Medicine in Bamberg. The hyperthermia treatment is then carried out in a cycle of two treatments per week, with at least one day in between, over a period of three weeks, according to the manufacturer's instructions. According to the guidelines, the rectal (possibly vaginal) temperature (as body core temperature), heart rate and oxygen saturation (Sp02) are continuously determined during the hyperthermia treatment. During the treatment, continuous supervision by trained personnel is guaranteed, and a doctor is on call.
Study NCT05135936 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham-Group
Description: The number of treatments is equal to the number of treatments in the intervention group.
Study NCT00884078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally adapted manualized problem solving training
Description: The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
Study NCT01816932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Visit
Description: The intervention is the location of the insertion visit.
Study NCT01816932 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Office visit
Study NCT02496364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Study NCT00753675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474, Vandetanib
Description: 300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT00753675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474, Vandetanib
Description: 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT00753675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT00753675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT00753675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ZD6474
Description: Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum based chemotherapy
Description: q1-3W according to physician's preference
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: q1-3W according to physician's preference
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel based chemotherapy
Description: q1-3W according to physician's preference
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel based chemotherapy
Description: q1-3W according to physician's preference
Study NCT04821843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherpay
Description: 40-50Gy/1.8-2.2Gy/20-25f
Study NCT04821843 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Radical esophagectomy
Study NCT04821843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical esophagectomy
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunotherapy
Description: Anti-PD-1/PD-L1 Antibody
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Anti-PD-1/PD-L1 Antibody
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU Analog based chemotherpay
Description: W1-5 qW or d1-14, q3W according to physician's preference
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Analog based chemotherpay
Description: W1-5 qW or d1-14, q3W according to physician's preference
Study NCT04821843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nimotuzumab
Description: 200-400mg, d1,qW